Posted by Michael Wonder on 10 Feb 2022
SMC approves Biogen’s Vumerity for patients with multiple sclerosis
9 February 2022 - The new, at home oral treatment has been developed for adults in Scotland living with relapsing-remitting multiple sclerosis.
Biogen’s Vumerity (diroximel fumarate) has been approved by the Scottish Medicines Consortium as an oral treatment for adults with relapsing-remitting multiple sclerosis.
